Hepatitis B: The pathway to recovery through treatment

被引：17

作者：

Hollinger, F. Blaine

Lau, Daryl T. -Y.

机构：

[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Mol Virol & Microbiol, Eugene B Casey Hepatitis Res Ctr, Houston, TX 77030 USA

[3] Baylor Coll Med, Diagnost Lab, Houston, TX 77030 USA

[4] Univ Texas, Med Branch, Div Gastroenterol & Hepatol, Dept Internal Med, Galveston, TX 77555 USA

[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

来源：

GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2006年 / 35卷 / 02期

关键词：

D O I：

10.1016/j.gtc.2006.03.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatitis B is a major public health problem in the world today. Since 1985, the number of reported cases has declined as a direct result of universal immunization of neonates, vaccination of at-risk populations, lifestyle or behavioral changes in high-risk groups, refinements in die screening of blood donors, and the use of virally inactivated or genetically engineered products in patients with bleeding disorders. New and potent antiviral agents being developed and evaluated provide hope and optimism for those who are chronically infected with hepatitis B virus. Prevention remains the most effective strategy in the global management of hepatitis B virus. Universal immunization programs prevent hepatitis B virus transmission and circumvent acute and chronic infection.

引用

页码：425 / +

页数：38

共 122 条

[1]

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].